PMID- 30603310
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201001
IS  - 2190-1678 (Print)
IS  - 2190-1686 (Electronic)
IS  - 2190-1678 (Linking)
VI  - 8
IP  - 1
DP  - 2017 Mar
TI  - Effects of ipragliflozin, a selective sodium-glucose co-transporter 2 inhibitor, 
      on blood pressure in Japanese patients with type 2 diabetes mellitus: a pooled 
      analysis of six randomized, placebo-controlled clinical trials.
PG  - 76-86
LID - 10.1007/s13340-016-0283-x [doi]
AB  - Our aim was to examine the effects of ipragliflozin, a selective sodium-glucose 
      co-transporter 2 inhibitor, on blood pressure in Japanese patients with type 2 
      diabetes mellitus (T2DM). We conducted a pooled analysis of double-blind trials 
      of Japanese T2DM patients, randomized to 50 mg ipragliflozin or placebo, with 
      patient-level data for the change in systolic blood pressure (SBP) and diastolic 
      blood pressure (DBP) from baseline to end of treatment (12-24 weeks). Data from 
      six trials were analyzed: ipragliflozin was administered as monotherapy in two; 
      in combination with metformin, pioglitazone, or sulfonylurea in one each; and in 
      combination with prior therapy in patients with renal impairment in one. Overall, 
      628 and 368 patients were treated with ipragliflozin and placebo, respectively. 
      The placebo-adjusted mean changes (95 % confidence interval) in SBP and DBP 
      (mmHg) were -2.8 (-4.4, -1.3, P < 0.001) and -1.6 (-2.7, -0.6, P < 0.002), 
      respectively, in all patients. The reductions in SBP and DBP were significantly 
      greater in patients with baseline SBP >/=140 mmHg [-5.5 (-9.1, -1.8) and -2.9 
      (-5.3, -0.5), respectively] than in patients with SBP <140 mmHg [-2.1 (-3.8, 
      -0.4) and -1.3 (-2.5, -0.1), respectively]. The reductions in SBP and DBP were 
      also significantly greater in the ipragliflozin group than in the placebo group 
      in patients treated with [-2.8 (-5.1, -0.4) and -2.4 (-4.0, -0.8), respectively] 
      or without [-3.0 (-5.0, -1.0) and -1.0 (-2.4, 0.4), respectively] concomitant 
      antihypertensive therapy. In conclusion, this pooled analysis showed that 
      ipragliflozin was associated with significant reductions in SBP and DBP compared 
      with placebo.
FAU - Kashiwagi, Atsunori
AU  - Kashiwagi A
AD  - Kusatsu General Hospital, 1660 Yabase-cho, Kusatsu, Shiga Japan.
FAU - Yoshida, Satoshi
AU  - Yoshida S
AD  - 2Astellas Pharma Inc., Tokyo, Japan. GRID: grid.418042.b
FAU - Kawamuki, Kosei
AU  - Kawamuki K
AD  - 2Astellas Pharma Inc., Tokyo, Japan. GRID: grid.418042.b
FAU - Nakamura, Ichiro
AU  - Nakamura I
AD  - 2Astellas Pharma Inc., Tokyo, Japan. GRID: grid.418042.b
FAU - Kazuta, Kenichi
AU  - Kazuta K
AD  - 2Astellas Pharma Inc., Tokyo, Japan. GRID: grid.418042.b
FAU - Ueyama, Eiji
AU  - Ueyama E
AD  - 2Astellas Pharma Inc., Tokyo, Japan. GRID: grid.418042.b
FAU - Takahashi, Hideyuki
AU  - Takahashi H
AD  - 2Astellas Pharma Inc., Tokyo, Japan. GRID: grid.418042.b
FAU - Akiyama, Noriko
AU  - Akiyama N
AD  - 2Astellas Pharma Inc., Tokyo, Japan. GRID: grid.418042.b
FAU - Kondo, Yoshinori
AU  - Kondo Y
AD  - Kotobuki Pharmaceutical Co., Ltd., Nagano, Japan.
FAU - Ogihara, Toshio
AU  - Ogihara T
AD  - 4Morinomiya University of Medical Sciences, Osaka, Japan. GRID: grid.440914.c
LA  - eng
PT  - Journal Article
DEP - 20160909
PL  - Japan
TA  - Diabetol Int
JT  - Diabetology international
JID - 101553224
PMC - PMC6224932
OTO - NOTNLM
OT  - Blood pressure
OT  - Efficacy
OT  - Ipragliflozin
OT  - Pooled analysis
OT  - Sodium-glucose co-transporter 2
COIS- AK has acted as a consultant for Astellas Pharma Inc. and has received consulting 
      fees/honoraria from Astellas Pharma Inc. TO has acted as a consultant for 
      Kotobuki Pharmaceutical Co., Ltd., and has received consulting fees/honoraria 
      from Kotobuki Pharmaceutical Co., Ltd. YK is an employee of Kotobuki 
      Pharmaceutical Co., Ltd. The other authors are employees of Astellas Pharma Inc., 
      Japan.All included studies in this analysis were conducted in accordance with the 
      ethical standards of the responsible committee on human experimentation 
      (institutional and national) and with the Helsinki Declaration of 1964 and later 
      versions. Informed consent or a substitute for it was obtained from all patients 
      for being included in the studies.
EDAT- 2016/09/09 00:00
MHDA- 2016/09/09 00:01
PMCR- 2017/09/09
CRDT- 2019/01/04 06:00
PHST- 2016/03/30 00:00 [received]
PHST- 2016/08/15 00:00 [accepted]
PHST- 2019/01/04 06:00 [entrez]
PHST- 2016/09/09 00:00 [pubmed]
PHST- 2016/09/09 00:01 [medline]
PHST- 2017/09/09 00:00 [pmc-release]
AID - 283 [pii]
AID - 10.1007/s13340-016-0283-x [doi]
PST - epublish
SO  - Diabetol Int. 2016 Sep 9;8(1):76-86. doi: 10.1007/s13340-016-0283-x. eCollection 
      2017 Mar.